Logo do repositório
 
Publicação

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure

2022-12-21Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorMetra, Marco
dc.contributor.authorPagnesi, Matteo
dc.contributor.authorClaggett, Brian L.
dc.contributor.authorDíaz, Rafael
dc.contributor.authorFelker, G. Michael
dc.contributor.authorMcMurray, John J.V.
dc.contributor.authorSolomon, Scott D.
dc.contributor.authorBonderman, Diana
dc.contributor.authorFang, James C.
dc.contributor.authorFonseca, Cândida
dc.contributor.authorGoncalvesova, Eva
dc.contributor.authorHowlett, Jonathan G.
dc.contributor.authorLi, Jing
dc.contributor.authorO'Meara, Eileen
dc.contributor.authorMiao, Zi Michael
dc.contributor.authorAbbasi, Siddique A.
dc.contributor.authorHeitner, Stephen B.
dc.contributor.authorKupfer, Stuart
dc.contributor.authorMalik, Fady I.
dc.contributor.authorTeerlink, John R.
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblEuropean Society of Cardiology | Oxford University Press
dc.date.accessioned2023-01-09T22:16:34Z
dc.date.available2023-01-09T22:16:34Z
dc.date.issued2022-12-21
dc.descriptionFunding: The GALACTIC-HF trial was funded by Amgen, Cytokinetics, and Servier
dc.description.abstractAIM: Patients with heart failure with reduced ejection fraction and low systolic blood pressure (SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical treatment. Omecamtiv mecarbil may be particularly helpful in such patients. This study examined its efficacy and tolerability in patients with SBP ≤100 mmHg enrolled in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF). METHODS AND RESULTS: The GALACTIC-HF enrolled patients with baseline SBP ≥85 mmHg with a primary outcome of time to cardiovascular death or first heart failure event. In this analysis, patients were divided according to their baseline SBP (≤100 vs. >100 mmHg). Among the 8232 analysed patients, 1473 (17.9%) had baseline SBP ≤100 mmHg and 6759 (82.1%) had SBP >100 mmHg. The primary outcome occurred in 715 (48.5%) and 2415 (35.7%) patients with SBP ≤100 and >100 mmHg, respectively. Patients with lower SBP were at higher risk of adverse outcomes. Omecamtiv mecarbil, compared with placebo, appeared to be more effective in reducing the primary composite endpoint in patients with SBP ≤100 mmHg [hazard ratio (HR), 0.81; 95% confidence interval (CI), 0.70-0.94] compared with those with SBP >100 mmHg (HR, 0.95; 95% CI, 0.88-1.03; P-value for interaction = 0.051). In both groups, omecamtiv mecarbil did not change SBP values over time and did not increase the risk of adverse events, when compared with placebo. CONCLUSION: In GALACTIC-HF, risk reduction of heart failure outcomes with omecamtiv mecarbil compared with placebo was large and significant in patients with low SBP. Omecamtiv mecarbil did not affect SBP and was well tolerated independent of SBP values.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent11
dc.format.extent913370
dc.identifier.doi10.1093/eurheartj/ehac293
dc.identifier.issn0195-668X
dc.identifier.otherPURE: 49544493
dc.identifier.otherPURE UUID: ed28f634-32eb-46d1-a9dd-dd19aac031d7
dc.identifier.otherScopus: 85144595125
dc.identifier.otherPubMed: 35675469
dc.identifier.otherWOS: 000807755600001
dc.identifier.urihttp://hdl.handle.net/10362/147237
dc.identifier.urlhttps://www.scopus.com/pages/publications/85144595125
dc.language.isoeng
dc.peerreviewedyes
dc.subjectCardiovascular outcomes trial
dc.subjectHeart failure
dc.subjectInotrope
dc.subjectMyotrope
dc.subjectOmecamtiv mecarbil
dc.subjectCardiology and Cardiovascular Medicine
dc.titleEffects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressureen
dc.title.subtitlethe GALACTIC-HF trialen
dc.typejournal article
degois.publication.firstPage5006
degois.publication.issue48
degois.publication.lastPage5016
degois.publication.titleEuropean Heart Journal
degois.publication.volume43
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
ehac293.pdf
Tamanho:
891.96 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica